Skip to content

Clinical validation of a novel rapid detection system for Mycobacterium tuberculosis based on the CRISPR-Cas system.

Performance evaluation of CRISPR-TB in detecting Mycobacterium tuberculosis in clinical samples

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107513
Enrollment
Unknown
Registered
2025-08-13
Start date
2025-08-16
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Gold Standard:Mycobacterium tuberculosis culture and Xpert Clinical diagnostic reference standard: *Health Industry Standard of the People's Republic of China: Diagnosis of Pulmonary Tuberculosis (
Index test:A highly sensitive diagnostic system for Mycobacterium tuberculosis, namely NuRapid Detection Analyzer (NDA-TB), has been developed based on the CRISPR-Cas system.

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Any age, any gender; 2. Patients suspected of having tuberculosis according to the subject's clinical manifestations (such as cough and sputum > 2 weeks, low-grade fever in the afternoon, night sweats, etc.), laboratory tests (TST, IGRA, etc.) and imaging test results (such as chest X-ray or CT); 3. If condition 2 is not met), it is necessary to be a close contact of a bacteriological confirmed tuberculosis patient, and complete chest CT and blood IGRA testing 4. Receiving antimycobacterial drug treatment for less than 7 days; 5. No form of anti-tuberculosis therapy in the past 3 months.

Exclusion criteria

Exclusion criteria: 1. The subject or his/her guardian is unable to sign the informed consent form or withdraw the informed consent form midway; 2. The test sample is insufficient to complete the test or the test is unsuccessful (contamination, error report, etc.); 3. No Xpert test results available (within 7 days of sampling date); 4. Unable to obtain clear clinical diagnosis results;

Design outcomes

Primary

MeasureTime frame
Sensitivity;Specificity;

Countries

China

Contacts

Public ContactYang Yang

Shanghai Public Health Clinical Center

2533384031@qq.com+86 153 0057 2587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026